Titre : Industrie pharmaceutique

Industrie pharmaceutique : Questions médicales fréquentes

Termes MeSH sélectionnés :

Logical Observation Identifiers Names and Codes
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Industrie pharmaceutique : Questions médicales les plus fréquentes", "headline": "Industrie pharmaceutique : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Industrie pharmaceutique : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-13", "dateModified": "2025-04-07", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Industrie pharmaceutique" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Secteur secondaire", "url": "https://questionsmedicales.fr/mesh/D066192", "about": { "@type": "MedicalCondition", "name": "Secteur secondaire", "code": { "@type": "MedicalCode", "code": "D066192", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.576.655" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Médicament orphelin", "alternateName": "Orphan Drug Production", "url": "https://questionsmedicales.fr/mesh/D009965", "about": { "@type": "MedicalCondition", "name": "Médicament orphelin", "code": { "@type": "MedicalCode", "code": "D009965", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "J01.576.655.750.600" } } } ], "about": { "@type": "MedicalCondition", "name": "Industrie pharmaceutique", "alternateName": "Drug Industry", "code": { "@type": "MedicalCode", "code": "D004345", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Beatriz G de la Torre", "url": "https://questionsmedicales.fr/author/Beatriz%20G%20de%20la%20Torre", "affiliation": { "@type": "Organization", "name": "KRISP, College of Health Sciences, University of KwaZulu-Natal, Durban 4001, South Africa." } }, { "@type": "Person", "name": "Fernando Albericio", "url": "https://questionsmedicales.fr/author/Fernando%20Albericio", "affiliation": { "@type": "Organization", "name": "School of Chemistry and Physics, University of KwaZulu-Natal, Durban 4001, South Africa." } }, { "@type": "Person", "name": "Christophe Tistaert", "url": "https://questionsmedicales.fr/author/Christophe%20Tistaert", "affiliation": { "@type": "Organization", "name": "Small Molecules Pharmaceutical Development, Drug Product Development, Biopharmaceutics, Janssen Research and Development, Beerse, Belgium." } }, { "@type": "Person", "name": "Tycho Heimbach", "url": "https://questionsmedicales.fr/author/Tycho%20Heimbach", "affiliation": { "@type": "Organization", "name": "Department of PK Sciences, PBPK and Biopharmaceutics Section, Novartis Institutes for BioMedical Research, East Hanover, New Jersey 07936." } }, { "@type": "Person", "name": "Joel Lexchin", "url": "https://questionsmedicales.fr/author/Joel%20Lexchin", "affiliation": { "@type": "Organization", "name": "School of Health Policy and Management, York University, Toronto, ON, Canada." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "ANOS1 accelerates the progression of esophageal cancer identified by multi-omic approaches.", "datePublished": "2024-05-15", "url": "https://questionsmedicales.fr/article/38859828", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.62347/SPCP3536" } }, { "@type": "ScholarlyArticle", "name": "Identifying the generalizable controls on insect associations of native and non-native trees.", "datePublished": "2024-05-12", "url": "https://questionsmedicales.fr/article/38742186", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ece3.11265" } }, { "@type": "ScholarlyArticle", "name": "Identifying Asian American lung cancer disparities: A novel analytic approach.", "datePublished": "2024-04-22", "url": "https://questionsmedicales.fr/article/39296463", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.xjon.2024.04.010" } }, { "@type": "ScholarlyArticle", "name": "The immune landscape of sepsis and using immune clusters for identifying sepsis endotypes.", "datePublished": "2024-04-19", "url": "https://questionsmedicales.fr/article/38707899", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fimmu.2024.1287415" } }, { "@type": "ScholarlyArticle", "name": "Right Ventricular \"Bubble Time\" to Identify Patients With Right Ventricular Dysfunction.", "datePublished": "2024-04-10", "url": "https://questionsmedicales.fr/article/38597847", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1016/j.annemergmed.2024.02.005" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Technologie, industrie et agriculture", "item": "https://questionsmedicales.fr/mesh/D013676" }, { "@type": "ListItem", "position": 3, "name": "Industrie", "item": "https://questionsmedicales.fr/mesh/D007221" }, { "@type": "ListItem", "position": 4, "name": "Secteur secondaire", "item": "https://questionsmedicales.fr/mesh/D066192" }, { "@type": "ListItem", "position": 5, "name": "Industrie pharmaceutique", "item": "https://questionsmedicales.fr/mesh/D004345" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Industrie pharmaceutique - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Industrie pharmaceutique", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Industrie pharmaceutique", "description": "Comment évaluer l'efficacité d'un médicament ?\nQu'est-ce qu'une étude de phase III ?\nQuels sont les critères d'inclusion dans un essai ?\nComment sont mesurés les effets secondaires ?\nQu'est-ce qu'un placebo ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Logical+Observation+Identifiers+Names+and+Codes&page=1000#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Industrie pharmaceutique", "description": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?\nComment reconnaître une allergie médicamenteuse ?\nQuels signes d'overdose sont fréquents ?\nQuels symptômes d'une interaction médicamenteuse ?\nComment identifier un effet secondaire rare ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Logical+Observation+Identifiers+Names+and+Codes&page=1000#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Industrie pharmaceutique", "description": "Comment prévenir les effets indésirables des médicaments ?\nQuelles sont les bonnes pratiques de prescription ?\nComment sensibiliser aux risques médicamenteux ?\nQuels conseils pour éviter les interactions médicamenteuses ?\nComment gérer les prescriptions multiples ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Logical+Observation+Identifiers+Names+and+Codes&page=1000#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Industrie pharmaceutique", "description": "Comment sont développés les nouveaux médicaments ?\nQu'est-ce qu'un médicament générique ?\nComment fonctionne la thérapie ciblée ?\nQu'est-ce qu'un médicament orphelin ?\nComment se déroule la mise sur le marché d'un médicament ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Logical+Observation+Identifiers+Names+and+Codes&page=1000#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Industrie pharmaceutique", "description": "Quelles complications peuvent survenir avec les médicaments ?\nComment gérer une réaction allergique grave ?\nQuels sont les risques de surdosage ?\nComment prévenir les complications liées aux traitements ?\nQuelles sont les complications des médicaments anticancéreux ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Logical+Observation+Identifiers+Names+and+Codes&page=1000#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Industrie pharmaceutique", "description": "Quels facteurs augmentent le risque d'effets secondaires ?\nComment l'alcool influence-t-il les médicaments ?\nQuels médicaments sont à risque pour les personnes âgées ?\nComment les maladies chroniques affectent-elles la médication ?\nQuels sont les risques liés à l'automédication ?", "url": "https://questionsmedicales.fr/mesh/D004345?mesh_terms=Logical+Observation+Identifiers+Names+and+Codes&page=1000#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment évaluer l'efficacité d'un médicament ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité est évaluée par des essais cliniques et des études de marché." } }, { "@type": "Question", "name": "Qu'est-ce qu'une étude de phase III ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "C'est une étude qui teste l'efficacité d'un médicament sur un grand nombre de patients." } }, { "@type": "Question", "name": "Quels sont les critères d'inclusion dans un essai ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les critères d'inclusion définissent les caractéristiques des participants éligibles." } }, { "@type": "Question", "name": "Comment sont mesurés les effets secondaires ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires sont mesurés par des rapports de patients et des études post-commercialisation." } }, { "@type": "Question", "name": "Qu'est-ce qu'un placebo ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "Un placebo est un traitement inactif utilisé comme référence dans les essais cliniques." } }, { "@type": "Question", "name": "Quels symptômes peuvent indiquer une réaction médicamenteuse ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des éruptions cutanées, des nausées ou des vertiges peuvent survenir." } }, { "@type": "Question", "name": "Comment reconnaître une allergie médicamenteuse ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Les allergies se manifestent par des démangeaisons, des rougeurs ou un gonflement." } }, { "@type": "Question", "name": "Quels signes d'overdose sont fréquents ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les signes incluent confusion, somnolence, et troubles respiratoires." } }, { "@type": "Question", "name": "Quels symptômes d'une interaction médicamenteuse ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Des symptômes comme des vertiges, des palpitations ou des troubles digestifs peuvent apparaître." } }, { "@type": "Question", "name": "Comment identifier un effet secondaire rare ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Les effets secondaires rares sont souvent identifiés par des études de pharmacovigilance." } }, { "@type": "Question", "name": "Comment prévenir les effets indésirables des médicaments ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par une prescription appropriée et une surveillance des patients." } }, { "@type": "Question", "name": "Quelles sont les bonnes pratiques de prescription ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Les bonnes pratiques incluent l'évaluation des antécédents médicaux et la communication avec le patient." } }, { "@type": "Question", "name": "Comment sensibiliser aux risques médicamenteux ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "La sensibilisation se fait par des campagnes d'information et des formations pour les professionnels." } }, { "@type": "Question", "name": "Quels conseils pour éviter les interactions médicamenteuses ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Il est conseillé de toujours informer le médecin de tous les médicaments pris, y compris les OTC." } }, { "@type": "Question", "name": "Comment gérer les prescriptions multiples ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique une coordination entre les différents prescripteurs et un suivi régulier." } }, { "@type": "Question", "name": "Comment sont développés les nouveaux médicaments ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Les nouveaux médicaments sont développés par la recherche, les essais cliniques et l'approbation réglementaire." } }, { "@type": "Question", "name": "Qu'est-ce qu'un médicament générique ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Un médicament générique est une version d'un médicament de marque, généralement moins coûteuse." } }, { "@type": "Question", "name": "Comment fonctionne la thérapie ciblée ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "La thérapie ciblée agit sur des molécules spécifiques impliquées dans la maladie." } }, { "@type": "Question", "name": "Qu'est-ce qu'un médicament orphelin ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Un médicament orphelin est destiné à traiter des maladies rares, souvent sans alternatives." } }, { "@type": "Question", "name": "Comment se déroule la mise sur le marché d'un médicament ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "La mise sur le marché nécessite des essais cliniques, une évaluation réglementaire et une approbation." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir avec les médicaments ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des réactions allergiques, des surdosages et des interactions." } }, { "@type": "Question", "name": "Comment gérer une réaction allergique grave ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Une réaction allergique grave nécessite une intervention médicale immédiate, comme l'adrénaline." } }, { "@type": "Question", "name": "Quels sont les risques de surdosage ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "Le surdosage peut entraîner des dommages organiques, des troubles neurologiques ou la mort." } }, { "@type": "Question", "name": "Comment prévenir les complications liées aux traitements ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par un suivi régulier et une évaluation des effets secondaires." } }, { "@type": "Question", "name": "Quelles sont les complications des médicaments anticancéreux ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent des infections, des nausées et des troubles sanguins." } }, { "@type": "Question", "name": "Quels facteurs augmentent le risque d'effets secondaires ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "L'âge, le poids, les maladies préexistantes et les interactions médicamenteuses augmentent le risque." } }, { "@type": "Question", "name": "Comment l'alcool influence-t-il les médicaments ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "L'alcool peut intensifier les effets des médicaments, augmentant le risque d'effets indésirables." } }, { "@type": "Question", "name": "Quels médicaments sont à risque pour les personnes âgées ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Les médicaments à risque incluent les sédatifs, les anticoagulants et certains analgésiques." } }, { "@type": "Question", "name": "Comment les maladies chroniques affectent-elles la médication ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Les maladies chroniques peuvent modifier la réponse aux médicaments et augmenter les effets secondaires." } }, { "@type": "Question", "name": "Quels sont les risques liés à l'automédication ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "L'automédication peut entraîner des interactions, des surdosages et des retards de traitement." } } ] } ] }

Sources (10000 au total)

Identifying Asian American lung cancer disparities: A novel analytic approach.

Asian Americans include heterogeneous subpopulations with unique burden as the only racial group with cancer as the leading cause of death. The purpose of the study was to identify differences in clin... Patients with lung cancer from 2016 National Cancer Database were divided into East Asian, Southeast Asian, South Asian subgroups based on geographic origins, and a composite Asian American group with... A total of 825,448 patients were analyzed. Asian Americans were underrepresented relative to White non-Hispanics in all clinical stages except IIIB and IV. In clinical stage IV, Asian Americans (51.0%... This is the first study to address lung cancer disparity in Asian American subgroups employing a novel analytical approach. Asian American subgroups demonstrated more advanced lung cancer diagnosis ye...

The immune landscape of sepsis and using immune clusters for identifying sepsis endotypes.

The dysregulated immune response to sepsis still remains unclear. Stratification of sepsis patients into endotypes based on immune indicators is important for the future development of personalized th... The indicators involved in innate, cellular, and humoral immune cells, inhibitory immune cells, and cytokines were simultaneously assessed in 90 sepsis patients and 40 healthy controls. Unsupervised k... We depicted that the impairment of innate and adaptive immunity accompanying increased inflammation was the most prominent feature in patients with sepsis. However, using immune indicators for disting... We depicted the immune landscape of patients with sepsis and identified three distinct immune endotypes with different survival rates. Cluster membership could be predicted with a model based on immun...

Right Ventricular "Bubble Time" to Identify Patients With Right Ventricular Dysfunction.

We propose a novel method of evaluating right ventricular (RV) dysfunction in the emergency department (ED) using RV "bubble time"-the duration of time bubbles from a saline solution flush are visuali... This prospective diagnostic accuracy study enrolled a convenience sample of hemodynamically stable patients in the ED. A sonographer administered a 10-mL saline solution flush into the patient's intra... Of 196 patients, median age was 67 year, and half were women, with 69 (35.2%) having RV dysfunction. Median RV bubble time among patients with RV dysfunction was 62 seconds (interquartile range [IQR]:... In patients in the ED, an RV bubble time of 40 or more seconds had high sensitivity in identifying patients with RV dysfunction, whereas an RV bubble time of less than 40 seconds had good specificity ...

Capi-score: a quantitative algorithm for identifying disease patterns in nailfold videocapillaroscopy.

The European Alliance of Associations for Rheumatology (EULAR) supports the use of nailfold videocapillaroscopy (NVC) to identify disease patterns (DPs) associated with systemic sclerosis (SSc) and Ra... NVCs were examined by 9 capillaroscopists. Those NVCs whose DPs were consensually agreed (≥2 out of 3 interobservers) were subsequently analysed with an in-house developed software. Each variable's re... Eight-hundred and fifty-one NVCs (21 957 images) whose DPs had been consensually agreed were software-analysed. Appropriate cut-offs set in capillary density and percentage of abnormal and giant capil... The CAPI-Score algorithm may become a useful tool to assign DPs by overcoming the limitations of subjectivity....